Evidence map›Paper›PMID 32078034›Full record

Trial reportEuropean archives of psychiatry and clinical neuroscience2021

Intravenous arketamine for treatment-resistant depression: open-label pilot study.

Gustavo C Leal, Igor D Bandeira, Fernanda S Correia-Melo, Manuela Telles, Rodrigo P Mello, Flavia Vieira, Cassio S Lima, Ana Paula Jesus-Nunes, Lívia N F Guerreiro-Costa, Roberta F Marback and 11 more

Open access · greenAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in European archives of psychiatry and clinical neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
106citing papers in PubMed, 9 pooled it
24.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

106 citing papers in PubMed, 9 syntheses or guidelines pooled it, 251 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Trial
  17. Review
  18. Review
  19. Article
  20. Review

46 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 4 countries.

Gustavo C LealHospital Universitário Professor Edgard Santos, Serviço de Psiquiatria, Universidade Federal da Bahia, 3º andar, Rua Dr. Augusto Viana S/N, Salvador, Bahia, 40110-060, Brazil.
Igor D BandeiraLaboratório de Neuropsicofarmacologia, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Fernanda S Correia-MeloLaboratório de Neuropsicofarmacologia, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Manuela TellesLaboratório de Neuropsicofarmacologia, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Rodrigo P MelloLaboratório de Neuropsicofarmacologia, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Flavia VieiraLaboratório de Neuropsicofarmacologia, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Cassio S LimaLaboratório de Neuropsicofarmacologia, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Ana Paula Jesus-NunesLaboratório de Neuropsicofarmacologia, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Lívia N F Guerreiro-CostaLaboratório de Neuropsicofarmacologia, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Roberta F MarbackLaboratório de Neuropsicofarmacologia, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Ana Teresa Caliman-FontesLaboratório de Neuropsicofarmacologia, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Breno L S MarquesLaboratório de Neuropsicofarmacologia, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Marília L O BezerraLaboratório de Neuropsicofarmacologia, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Alberto L Dias-NetoLaboratório de Neuropsicofarmacologia, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Samantha S SilvaLaboratório de Neuropsicofarmacologia, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Aline S SampaioLaboratório de Neuropsicofarmacologia, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Gerard SanacoraDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Gustavo TureckiMcGill Group for Suicide Studies, Department of Psychiatry, Douglas Mental Health University Institute and McGill University, Montreal, Canada.
Colleen LooSchool of Psychiatry, University of New South Wales and Black Dog Institute, Sydney, NSW, Australia.
Acioly L T LacerdaLaboratório Interdisciplinar de Neurociências Clínicas, Universidade Federal de São Paulo, São Paulo, São Paulo, Brazil.
Lucas C QuarantiniHospital Universitário Professor Edgard Santos, Serviço de Psiquiatria, Universidade Federal da Bahia, 3º andar, Rua Dr. Augusto Viana S/N, Salvador, Bahia, 40110-060, Brazil. lcq@ufba.br.
Universidade Federal da Bahia · BRBlack Dog Institute · AUBrazilian Institute of Neuroscience and Neurotechnology · BRDouglas Mental Health University Institute · CAYale University · US

Funding

Programa de Pesquisa para o SUS 003/2017
6 · The paper itself

Abstract

We aimed to analyze the efficacy and safety of arketamine, the R(-)-enantiomer of ketamine, for treatment-resistant depression (TRD) in humans. Open-label pilot trial, seven subjects with TRD received a single intravenous infusion of arketamine (0.5 mg/kg); primary outcome was change in Montgomery-Åsberg Depression Rating Scale (MADRS) 24 h after. Mean MADRS dropped from 30.7 before infusion to 10.4 after one day, a mean difference of 20.3 points [CI 95% 13.6-27.0; p < 0.001]; dissociation was nearly absent. Arketamine might produce fast-onset and sustained antidepressant effects in humans with favorable safety profile, like previously reported with animals; further controlled-trials are needed.

Indexed as

Outcome Assessment, Health CareAdultAgedAntidepressive AgentsDepressive Disorder, Treatment-ResistantFemaleHumansInfusions, IntravenousKetamineMajor Depressive DisorderMiddle AgedPilot ProjectsPsychiatric Status Rating ScalesRemission InductionSeverity of Illness IndexAntidepressive AgentsKetamineArketamineKetamineMajor depressive disorderRapid-acting antidepressant(R)-KetamineTreatment-resistant depression

Identifiers

PMID32078034
OpenAlexW3007923795

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.